UNSPSC 51283210: Troleandomycin

This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but generally known as triacetyloleandomycin, which bears US NIH Compound Identifier 17675. European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG.

UNSPSC 51283210 Troleandomycin, a Commodity code, nominally covers a specific macrolide antibiotic, but recent state and local procurement activity under this code does not reflect purchases of troleandomycin itself. Instead, the code appears in solicitations for broader pharmaceutical warehouse supply and community health product procurement, including antibiotic tablets, naloxone, and drug deactivation systems. State and local governments use this code to tag pharmaceutical supply contracts that are executed through piggyback arrangements with established consortia or via direct competitive bidding for emergency-response and public-health products.

The Illinois Department of Public Health and Seminole County, Florida represent the issuing bodies in recent activity. Illinois awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate and ciprofloxacin hydrochloride tablets under an IFB process, with a 12-month initial term and two renewal options. Seminole County released an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, a two-year initial term with a one-year renewal option. Recent activity spans Florida and Illinois, with procurement driven by public health and emergency-response needs rather than routine pharmaceutical sourcing. The mismatch between the code's nominal scope (troleandomycin) and the actual goods being solicited (antibiotic tablets, naloxone, deactivation systems) suggests either broad code application or reclassification during procurement; vendors pursuing state and local opportunities under this code should expect to compete on pharmaceutical supply logistics, pricing, and delivery performance rather than specialty-drug expertise.